Trade AstraZeneca PLC - USD - AZN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.12 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 64.03 |
| Open | 65.63 |
| 1-Year Change | 2.13% |
| Day's Range | 65.52 - 66.36 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 22, 2024 | 65.57 | -0.13 | -0.20% | 65.70 | 66.39 | 65.40 |
| Nov 21, 2024 | 64.03 | 0.45 | 0.71% | 63.58 | 64.28 | 63.46 |
| Nov 20, 2024 | 63.14 | -0.62 | -0.97% | 63.76 | 63.83 | 62.81 |
| Nov 19, 2024 | 63.73 | 0.19 | 0.30% | 63.54 | 64.07 | 63.23 |
| Nov 18, 2024 | 63.31 | 0.44 | 0.70% | 62.87 | 63.59 | 62.68 |
| Nov 15, 2024 | 63.18 | -0.51 | -0.80% | 63.69 | 63.97 | 63.12 |
| Nov 14, 2024 | 64.98 | -0.36 | -0.55% | 65.34 | 65.92 | 64.91 |
| Nov 13, 2024 | 65.22 | -0.21 | -0.32% | 65.43 | 65.63 | 64.63 |
| Nov 12, 2024 | 65.13 | 1.76 | 2.78% | 63.37 | 66.18 | 62.85 |
| Nov 11, 2024 | 64.71 | -0.39 | -0.60% | 65.10 | 65.15 | 64.65 |
| Nov 8, 2024 | 64.46 | -0.25 | -0.39% | 64.71 | 64.98 | 64.22 |
| Nov 7, 2024 | 64.62 | 1.19 | 1.88% | 63.43 | 64.68 | 63.25 |
| Nov 6, 2024 | 63.79 | -0.45 | -0.70% | 64.24 | 64.72 | 63.66 |
| Nov 5, 2024 | 66.21 | -0.90 | -1.34% | 67.11 | 67.50 | 65.23 |
| Nov 4, 2024 | 71.37 | -0.41 | -0.57% | 71.78 | 73.61 | 70.95 |
| Nov 1, 2024 | 71.35 | -0.22 | -0.31% | 71.57 | 71.80 | 71.25 |
| Oct 31, 2024 | 71.09 | -0.39 | -0.55% | 71.48 | 71.86 | 71.05 |
| Oct 30, 2024 | 72.78 | 0.69 | 0.96% | 72.09 | 73.24 | 70.89 |
| Oct 29, 2024 | 75.15 | -0.26 | -0.34% | 75.41 | 75.73 | 75.00 |
| Oct 28, 2024 | 75.94 | 0.93 | 1.24% | 75.01 | 76.57 | 74.89 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
AstraZeneca - USD Company profile
About AstraZeneca plc (ADR)
AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc (ADR) revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.
Equity composition
Ordinary Shares $.25, 12/10, 2.4B auth. 1,409,023,452 issd.Insiders own 0.37%. 5/93, Company formed through spin-off of a wholly-owned subsidiary ICI Zeneca Limited. Basis: 1-for-1. *FY'01 Q's are restated for deferred tax. 07/15, 2-for-1, Stock Split.
| Industry: | Pharmaceuticals (NEC) |
1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com